Gower Bob G's Form 4 filing
Ensysce Biosciences, Inc. (ENSC) · filed Aug 18, 2026
- Accession no.
- 0001493152-26-038866
- Filed
- Aug 18, 2026, 6:06 AM ET
- Trade date
- Apr 23-Aug 7, 2026
- Filing delay
- 117 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market purchases total $444.2K. It was filed 117 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Gower Bob GCIK 0001136466 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 23, 2026 | Common Stock | PPurchaseAcquired | +508,614 | $0.484 | +$246,169.18 | 516,740 | Direct | |
| Aug 7, 2026 | Common Stock | PPurchaseAcquired | +400,000 | $0.495 | +$198,000 | 916,740 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 23, 2026 | Common Stock | CConversionAcquired | +254,307 | –F2 | – | 289,836 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Amendment and conversion, without payment of additional consideration, of two senior convertible promissory notes, aggregate principal amount $216,000, issued in 2023 into 254,307 shares of common stock as reported in Table 1 above and a warrant to purchase 254,307 shares of common stock as reported in Table II above. In April 2026, the outstanding principal amount, together with accrued and unpaid interest, was $246,169.
Referenced by the price of 1 transaction in Table II.